Last reviewed · How we verify

somatostatin, intravenous bolus

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Phase 3 active Small molecule

somatostatin, intravenous bolus is a Small molecule drug developed by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. It is currently in Phase 3 development.

At a glance

Generic namesomatostatin, intravenous bolus
SponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about somatostatin, intravenous bolus

What is somatostatin, intravenous bolus?

somatostatin, intravenous bolus is a Small molecule drug developed by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.

Who makes somatostatin, intravenous bolus?

somatostatin, intravenous bolus is developed by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (see full Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau pipeline at /company/fundaci-institut-de-recerca-de-l-hospital-de-la-santa-creu-i-sant-pau).

What development phase is somatostatin, intravenous bolus in?

somatostatin, intravenous bolus is in Phase 3.

Related